Glivec Research Today is a free monthly online journal that collates and summarizes the latest research about Glivec, including details on gleevec, imatinib, cancer, treatment, side-effects.

Volume 2 (2005), Issue 11 (November)

1. Treatment of elderly patients with acute lymphoblastic leukemia--evidence for a benefit of imatinib in BCR-ABL positive patients.
   Leuk Res, 29(12): 1381-6. [Abstract] [Full-text]
2. Elevated plasma levels of vascular endothelial growth factor is associated with marked splenomegaly in chronic myeloid leukemia.
   Leuk Lymphoma, 46(12): 1761-4. [Abstract] [Full-text]
3. An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development.
   Cancer Res, 65(21): 9633-6. [Abstract] [Full-text]
4. Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia.
   Oncogene, 24(48): 7213-23. [Abstract] [Full-text]
5. The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome Imatinib resistance.
   Leukemia. [Abstract] [Full-text]
6. Multidrug resistance proteins in gastrointestinal stromal tumors: site-dependent expression and initial response to imatinib.
   Clin Cancer Res, 11(21): 7593-8. [Abstract] [Full-text]
7. Follow-up of gastro-intestinal stromal tumours (GIST) during treatment with imatinib mesylate by abdominal MRI.
   Eur Radiol, 15(12): 2448-56. [Abstract] [Full-text]
8. Small bowel Gastrointestinal Stromal Tumors can physiologically alter gut motility before causing mechanical obstruction.
   Int Semin Surg Oncol, 2: 24. [Abstract] [Full-text]
9. The role of c-kit and imatinib mesylate in uveal melanoma.
   J Carcinog, 4: 19. [Abstract] [Full-text]
10. Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia.
    Dermatology, 211(4): 363-5. [Abstract] [Full-text]
11. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein.
    Cancer Cell, 8(5): 355-68. [Abstract] [Full-text]
12. Advanced-stage gastrointestinal stromal tumor treated with imatinib in a 12-year-old girl with a unique mutation of PDGFRA.
    J Pediatr Surg, 40(11): 1798-801. [Abstract] [Full-text]
13. Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.
    Biochem Biophys Res Commun, 338(3): 1307-15. [Abstract] [Full-text]
14. Assaying Bcr-Abl kinase activity and inhibition in whole cell extracts by phosphorylation of substrates immobilized on agarose beads.
    Anal Biochem, 347(1): 67-76. [Abstract] [Full-text]
15. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia.
    Blood, 106(12): 3948-54. [Abstract] [Full-text]
16. Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate.
    Blood, 106(12): 3958-61. [Abstract] [Full-text]
17. Role of tyrosine kinase inhibitors in cancer therapy.
    J Pharmacol Exp Ther, 315(3): 971-9. [Abstract] [Full-text]
18. Unexpected rapid progression of metastatic adenoid cystic carcinoma during treatment with imatinib mesylate.
    Head Neck, 27(12): 1022-7. [Abstract] [Full-text]
19. Multiple constitutional chromosome translocations of familial nature in Philadelphia chromosome-positive chronic myeloid leukemia: a report on a unique case.
    Int J Hematol, 82(4): 347-50. [Abstract] [Full-text]
20. Severe hepatic injury caused by imatinib mesylate administered for the treatment of chronic myeloid leukemia and the efficacy of prednisolone for its management.
    Int J Hematol, 82(4): 343-6. [Abstract] [Full-text]
21. Use of imatinib mesylate for favorable control of hypercalcemia mediated by parathyroid hormone-related protein in a patient with chronic myelogenous leukemia at blast phase.
    Int J Hematol, 82(4): 333-7. [Abstract] [Full-text]
22. Acute renal failure secondary to imatinib mesylate treatment in prostate cancer.
    Ann Pharmacother, 39(12): 2136-8. [Abstract] [Full-text]
23. Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL.
    Leukemia, 19(12): 2159-65. [Abstract] [Full-text]

© 2004-2008 Glivec Research Today. All Rights Reserved.